Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The document serves as a notification of transactions involving a person discharging managerial responsibility, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific director transaction notification and does not contain financial statements or performance metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The only change noted is a personal share acquisition by a company official.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investors
- Transaction Type: Acquisition of beneficial interest in ordinary shares.
- Individual: Mr. S M Bicknell (Person Discharging Managerial Responsibility).
- Details: Acquired 20 Ordinary shares on January 6, 2012, via dividend re-investment under Personal Equity Plans.
- Price: 1491.5 pence per share.
- Notification Date: The company was advised of the transaction on January 9, 2012.